NCT05913999
Serial PET MPI in Patients Undergoing Cancer Treatment
Enrolling by Invitation
Not specifiedAges 18+ObservationalUniversity of California, Los AngelesInvestigator-initiated
~60 participants
Updated 2025-08-06 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
PET myocardial perfusion imaging (MPI).
Measured over Baseline (within 1 month prior to the initiation of cancer treatment), during cancer treatment (estimated at 1-6 months), and within 1 month post-cancer treatment completion (approximately 2-9 months)
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Rene Packard, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Veterans Affairs oncology patients who will be initiating chemotherapy
Ability to give consent
Exclusion
Prior chemotherapy
Prior coronary revascularization (percutaneous coronary intervention, coronary artery bypass grafting)
Anyone with previous invasive or CT (computed tomography) angiogram demonstrating any lesion ≥ 50% stenosis
Known cardiomyopathy defined as rest ejection fraction \< 50%
History of heart and/or another organ transplant
Pregnancy or breast-feeding status
What this trial measures
- PET myocardial perfusion imaging (MPI).Baseline (within 1 month prior to the initiation of cancer treatment), during cancer treatment (estimated at 1-6 months), and within 1 month post-cancer treatment completion (approximately 2-9 months)
Change from baseline in number of patients with perfusion defects measured as % total perfusion deficit (TPD) of the left ventricular myocardium by PET
- PET myocardial blood flow (MBF) measurement.Baseline (within 1 month prior to the initiation of cancer treatment), during cancer treatment (estimated at 1-6 months), and within 1 month post-cancer treatment completion (approximately 2-9 months)
Change from baseline in number of patients with myocardial blood flow abnormalities measured as stress myocardial blood flow (SMBF) values \< 2 mL/min/g of left ventricular myocardium by PET